Antigen Information

General Information of This Antigen
Antigen ID
TAR0RKGHS
Antigen Name
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)
Gene Name
TNFRSF10B
Gene ID
8795
Synonym
DR5; KILLER; TRAILR2; TRICK2; ZTNFR9; Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;CD_antigen=CD262
Sequence
MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQD
LAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCD
SGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVH
KESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKV
LPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGV
NMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRK
LGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIED
HLLSSGKFMYLEGNADSAMS

    Click to Show/Hide
Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

    Click to Show/Hide
Uniprot Entry
TR10B_HUMAN
HGNC ID
HGNC:11905
KEGG ID
hsa:8795
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
Anti-DR5 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Anti-DR5 antibody-curcumin conjugate [1]
Curcumin
Arylamine N-acetyltransferase 2 (NAT2)
Mc-PEG-WDP
 ADC Info 
Zaptuzumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Oba01 [2]
MMAE
Microtubule (MT)
PY-MAA-Val-Cit-PABC
 ADC Info 
Zapadcine-1 [3]
Monomethyl auristatin D
Microtubule (MT)
PY-VC-PABC
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
RC-248
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
References
Ref 1 An anti-DR5 antibody-curcumin conjugate for the enhanced clearance of activated hepatic stellate cells. Int J Biol Macromol. 2021 Dec 1;192:1231-1239. doi: 10.1016/j.ijbiomac.2021.09.176. Epub 2021 Oct 6.
Ref 2 Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol Ther Oncolytics. 2021 Apr 29;21:329-339. doi: 10.1016/j.omto.2021.04.013. eCollection 2021 Jun 25.
Ref 3 A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.